Based on the fact that these five genes (GSS, GMPPA, SGPP2, OGDH, and PIK3CA) have prognostic utility in HP+ GC, they are attractive therapeutic targets and deserve further exploration, especially considering that treatment with chemotherapy and immunotherapy drugs may phenocopy the effects of the expression of these metabolic genes. This evidence concerns the gene SGPP2 and gastric cancer.